CN118161591A - 替维瑞克-tfa组合物 - Google Patents

替维瑞克-tfa组合物 Download PDF

Info

Publication number
CN118161591A
CN118161591A CN202410217838.XA CN202410217838A CN118161591A CN 118161591 A CN118161591 A CN 118161591A CN 202410217838 A CN202410217838 A CN 202410217838A CN 118161591 A CN118161591 A CN 118161591A
Authority
CN
China
Prior art keywords
tfa
molar ratio
tivalia
trifluoroacetate
tevereix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410217838.XA
Other languages
English (en)
Chinese (zh)
Inventor
盖伊·普兰德
弗朗索瓦·布蒂尼翁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antev Ltd
Original Assignee
Antev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antev Ltd filed Critical Antev Ltd
Publication of CN118161591A publication Critical patent/CN118161591A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202410217838.XA 2018-07-05 2019-07-02 替维瑞克-tfa组合物 Pending CN118161591A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18181945.9 2018-07-05
EP18181945.9A EP3590525A1 (en) 2018-07-05 2018-07-05 Teverelix-tfa composition
PCT/EP2019/067728 WO2020007857A1 (en) 2018-07-05 2019-07-02 Teverelix-tfa composition
CN201980041338.2A CN112423775B (zh) 2018-07-05 2019-07-02 替维瑞克-tfa组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980041338.2A Division CN112423775B (zh) 2018-07-05 2019-07-02 替维瑞克-tfa组合物

Publications (1)

Publication Number Publication Date
CN118161591A true CN118161591A (zh) 2024-06-11

Family

ID=62874669

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410217838.XA Pending CN118161591A (zh) 2018-07-05 2019-07-02 替维瑞克-tfa组合物
CN201980041338.2A Active CN112423775B (zh) 2018-07-05 2019-07-02 替维瑞克-tfa组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980041338.2A Active CN112423775B (zh) 2018-07-05 2019-07-02 替维瑞克-tfa组合物

Country Status (6)

Country Link
US (2) US11357818B2 (cg-RX-API-DMAC7.html)
EP (3) EP3590525A1 (cg-RX-API-DMAC7.html)
JP (3) JP7181318B2 (cg-RX-API-DMAC7.html)
CN (2) CN118161591A (cg-RX-API-DMAC7.html)
CA (1) CA3141519A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020007857A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases
EP4541365A1 (en) 2023-10-18 2025-04-23 Antev Limited Teverelix-tfa in a dosage regime for use in the treatment of prostate cancer
EP4643869A1 (en) 2024-05-03 2025-11-05 Antev Limited Use of gnrh antagonists such as teverelix to treat acute urinary retention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985723A (en) * 1971-09-07 1976-10-12 The University Of Mississippi Trifluoroacetylation process
US7098305B2 (en) * 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2008071984A1 (en) * 2006-12-13 2008-06-19 Ardana Bioscience Limited Administration of the gonadotropin-releasing hormone antagonist teverelix
CN105693844A (zh) * 2016-03-10 2016-06-22 泰州施美康多肽药物技术有限公司 一种促性腺激素释放激素类似物醋酸盐的制备方法
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Also Published As

Publication number Publication date
JP2025004006A (ja) 2025-01-14
JP2023027082A (ja) 2023-03-01
US20220273758A1 (en) 2022-09-01
US20210236588A1 (en) 2021-08-05
JP7181318B2 (ja) 2022-11-30
EP3817758B1 (en) 2022-01-05
CA3141519A1 (en) 2020-01-09
CN112423775A (zh) 2021-02-26
WO2020007857A1 (en) 2020-01-09
JP2021529165A (ja) 2021-10-28
US12070484B2 (en) 2024-08-27
US11357818B2 (en) 2022-06-14
EP4011373B1 (en) 2026-04-29
CN112423775B (zh) 2024-03-15
EP4011373C0 (en) 2026-04-29
EP4011373A1 (en) 2022-06-15
EP3817758A1 (en) 2021-05-12
EP3590525A1 (en) 2020-01-08

Similar Documents

Publication Publication Date Title
JP6811270B2 (ja) ランレオチドの持続放出用の医薬組成物
US12070484B2 (en) Teverelix-TFA composition
HU225691B1 (en) Aqueous formulations of peptides
US20230358472A1 (en) Lyophilization process and a teverelix-tfa lyophilizate obtained thereby
US12458680B2 (en) Reconstitutable teverelix-TFA composition
JP6151848B2 (ja) ゴセレリン徐放性マイクロスフェア医薬組成物
CN110248679A (zh) 包含至少一种GnRH拮抗剂的组合物
US20030092628A1 (en) Gonadotropin releasing hormone antagonist
WO2001000227A1 (en) Gonadotropin releasing hormone antagonist
CN122028929A (zh) 用于治疗前列腺癌的替维瑞克-tfa的给药方案

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination